Elizabeta Nemeth is a Professor of Medicine at the David Geffen School of Medicine at UCLA, and Director of the UCLA Center for Iron Disorders. She has made major contributions to the understanding of iron homeostasis and of its dysregulation in many diseases. She has described the role of hepcidin in various iron disorders including hereditary hemochromatosis, iron-loading anemias (e.g. β-thalassemia), and iron-restricted anemias associated with inflammation and chronic kidney disease. Elizabeta is currently serving as a standing member of the Molecular and Cellular Hematology Study Section of the National Institutes of Health. She is a member of the Board of Directors of the International Bioiron Society and a member of the Editorial Board of Blood. Elizabetha has helped start three biotechnology companies: Intrinsic LifeSciences, focused on developing iron diagnostics, Merganser Biotech, focused on developing hepcidin peptide therapeutics, and Silarus Therapeutics, focused on developing erythroferrone-targeted therapeutics.